ANDA 90884, held by ACS Dobfar. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 90884 (Ampicillin Sodium), held by ACS Dobfar, was first approved by FDA on Apr 3, 2013, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 3, 2013 | Original application | Approved | None posted |
| Ampicillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| May 1, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 30, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 30, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 3, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters